Targacept Completes Recruitment in Phase 2b Schizophrenia Trial of TC-5619

[at noodls] – Winston-Salem, North Carolina April 18, 2013 Targacept, Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company developing novel NNR Therapeuticsâ„¢, today announced that it has completed recruitment … more

View todays social media effects on TRGT

View the latest stocks trending across Twitter. Click to view dashboard

See who Targacept is hiring next, click here to view